Septerna (NASDAQ:SEPN) Earns Strong-Buy Rating from Analysts at Raymond James Financial

Raymond James Financial assumed coverage on shares of Septerna (NASDAQ:SEPN) in a report published on Friday, Marketbeat Ratings reports. The brokerage issued a strong-buy rating and a $38.00 price target on the stock.

A number of other research analysts also recently issued reports on the stock. Wells Fargo & Company upgraded shares of Septerna from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $18.00 to $28.00 in a research report on Friday, November 14th. Wall Street Zen upgraded shares of Septerna from a “buy” rating to a “strong-buy” rating in a report on Saturday. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 price objective on shares of Septerna in a research report on Friday, September 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research report on Wednesday, October 8th. Finally, HC Wainwright increased their price target on Septerna from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $31.00.

Septerna Trading Up 7.4%

SEPN opened at $29.58 on Friday. The company has a market cap of $1.32 billion, a P/E ratio of -19.59 and a beta of 3.80. The company’s 50 day moving average is $23.76 and its 200-day moving average is $16.97. Septerna has a 1-year low of $4.17 and a 1-year high of $30.50.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). The firm had revenue of $21.50 million during the quarter, compared to the consensus estimate of $24.50 million. Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%. On average, equities analysts forecast that Septerna will post -7.11 EPS for the current year.

Insiders Place Their Bets

In other news, SVP Daniel D. Long sold 3,501 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $18.06, for a total value of $63,228.06. Following the completion of the transaction, the senior vice president directly owned 92,911 shares of the company’s stock, valued at $1,677,972.66. This represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Septerna

Hedge funds have recently modified their holdings of the stock. Jacobs Levy Equity Management Inc. bought a new stake in shares of Septerna during the 3rd quarter valued at $673,000. PharVision Advisers LLC boosted its stake in Septerna by 17.5% in the 3rd quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock worth $224,000 after purchasing an additional 1,780 shares during the period. VR Adviser LLC grew its holdings in Septerna by 13.0% during the 3rd quarter. VR Adviser LLC now owns 610,808 shares of the company’s stock valued at $11,489,000 after buying an additional 70,355 shares in the last quarter. Verition Fund Management LLC bought a new stake in shares of Septerna during the third quarter valued at about $379,000. Finally, Millennium Management LLC lifted its holdings in shares of Septerna by 639.6% in the third quarter. Millennium Management LLC now owns 384,200 shares of the company’s stock worth $7,227,000 after buying an additional 332,256 shares in the last quarter.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.